275 related articles for article (PubMed ID: 15029258)
1. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
2. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells.
Nguyen TM; Arthur A; Hayball JD; Gronthos S
Stem Cells Dev; 2013 Oct; 22(20):2751-64. PubMed ID: 23711177
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of ephrin-Bs and their receptors in colon carcinoma.
Liu W; Ahmad SA; Jung YD; Reinmuth N; Fan F; Bucana CD; Ellis LM
Cancer; 2002 Feb; 94(4):934-9. PubMed ID: 11920461
[TBL] [Abstract][Full Text] [Related]
4. Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
Lee TH; Heo JH; Jeong JY; Lee GH; Park DS; Kim TH
Yonsei Med J; 2021 Aug; 62(8):679-690. PubMed ID: 34296545
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Tachibana M; Tonomoto Y; Hyakudomi R; Hyakudomi M; Hattori S; Ueda S; Kinugasa S; Yoshimura H
Dig Liver Dis; 2007 Aug; 39(8):725-32. PubMed ID: 17611172
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
Wu Q; Suo Z; Kristensen GB; Baekelandt M; Nesland JM
Gynecol Oncol; 2006 Jul; 102(1):15-21. PubMed ID: 16499955
[TBL] [Abstract][Full Text] [Related]
7. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Li X; Choi WW; Yan R; Yu H; Krasnoperov V; Kumar SR; Schuckman A; Klumpp DJ; Pan CX; Quinn D; Gill IS; Gill PS; Liu R
PLoS One; 2014; 9(8):e105326. PubMed ID: 25148033
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Gynecol Oncol; 2009 Jul; 114(1):84-8. PubMed ID: 19356789
[TBL] [Abstract][Full Text] [Related]
9. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
Magic Z; Sandström J; Perez-Tenorio G
Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
[TBL] [Abstract][Full Text] [Related]
10. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.
Kuang SQ; Bai H; Fang ZH; Lopez G; Yang H; Tong W; Wang ZZ; Garcia-Manero G
Blood; 2010 Mar; 115(12):2412-9. PubMed ID: 20061560
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
12. The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis.
Helbling PM; Saulnier DM; Brändli AW
Development; 2000 Jan; 127(2):269-78. PubMed ID: 10603345
[TBL] [Abstract][Full Text] [Related]
13. Altered expression patterns of EphrinB2 and EphB2 in human umbilical vessels and congenital venous malformations.
Diehl S; Bruno R; Wilkinson GA; Loose DA; Wilting J; Schweigerer L; Klein R
Pediatr Res; 2005 Apr; 57(4):537-44. PubMed ID: 15718372
[TBL] [Abstract][Full Text] [Related]
14. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
15. EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer.
Husa AM; Magić Ž; Larsson M; Fornander T; Pérez-Tenorio G
Oncotarget; 2016 Apr; 7(16):21362-80. PubMed ID: 26870995
[TBL] [Abstract][Full Text] [Related]
16. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Br J Cancer; 2008 Feb; 98(4):845-51. PubMed ID: 18231102
[TBL] [Abstract][Full Text] [Related]
18. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Takai N; Miyazaki T; Fujisawa K; Nasu K; Miyakawa I
Oncol Rep; 2001; 8(3):567-73. PubMed ID: 11295082
[TBL] [Abstract][Full Text] [Related]
19. Expression and localisation of ephrin-B1, EphB2, and EphB4 in the mouse testis during postnatal development.
Gofur MR; Alam J; Ogawa K
Reprod Biol; 2020 Sep; 20(3):321-332. PubMed ID: 32620380
[TBL] [Abstract][Full Text] [Related]
20. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.
Zamora DO; Davies MH; Planck SR; Rosenbaum JT; Powers MR
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2175-82. PubMed ID: 15914639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
